Literature DB >> 22992140

Immune modulation in Pompe disease treated with enzyme replacement therapy.

Suhrad G Banugaria, Trusha T Patel, Priya S Kishnani.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22992140     DOI： 10.1586/eci.12.40

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


× No keyword cloud information.
  13 in total

Review 1.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

2.  Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses.

Authors:  Zoheb B Kazi; Sean N Prater; Joyce A Kobori; David Viskochil; Carrie Bailey; Renuka Gera; David W Stockton; Paul McIntosh; Amy S Rosenberg; Priya S Kishnani
Journal:  JCI Insight       Date:  2016-07-21

3.  Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease.

Authors:  Jennifer L Schneider; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2016-07-31       Impact factor: 3.534

4.  Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.

Authors:  Roberto A Maldonado; Robert A LaMothe; Joseph D Ferrari; Ai-Hong Zhang; Robert J Rossi; Pallavi N Kolte; Aaron P Griset; Conlin O'Neil; David H Altreuter; Erica Browning; Lloyd Johnston; Omid C Farokhzad; Robert Langer; David W Scott; Ulrich H von Andrian; Takashi Kei Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

5.  High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.

Authors:  Mugdha Rairikar; Zoheb B Kazi; Ankit Desai; Crista Walters; Amy Rosenberg; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-05-18       Impact factor: 4.797

Review 6.  The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.

Authors:  A Broomfield; S A Jones; S M Hughes; B W Bigger
Journal:  J Inherit Metab Dis       Date:  2016-02-16       Impact factor: 4.982

7.  Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher.

Authors:  Fiona Y Glassman; Jennifer L Schneider; Radha Ramakrishnan; Robert K Dingman; Murali Ramanathan; Richard B Bankert; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2018-04-09       Impact factor: 3.534

Review 8.  Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.

Authors:  Giancarlo Parenti; Generoso Andria; Kenneth J Valenzano
Journal:  Mol Ther       Date:  2015-04-16       Impact factor: 11.454

9.  Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

Authors:  Suhrad G Banugaria; Sean N Prater; Trusha T Patel; Stephanie M Dearmey; Christie Milleson; Kathryn B Sheets; Deeksha S Bali; Catherine W Rehder; Julian A J Raiman; Raymond A Wang; Francois Labarthe; Joel Charrow; Paul Harmatz; Pranesh Chakraborty; Amy S Rosenberg; Priya S Kishnani
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.

Authors:  Haiqing Yi; Fengqin Gao; Stephanie Austin; Priya S Kishnani; Baodong Sun
Journal:  Mol Genet Metab Rep       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.